SCHEMBL4153424

SCHEMBL4153424

O=C(NCCc1cccnc1)c1ccnc2[nH]c(-c3ccco3)nc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.55
CACNA1B Q00975 1/20 0.54
APBA1 Q02410 1/20 0.54
ADORA2A P29274 7/20 0.45
ADORA1 P30542 7/20 0.45
ADORA3 P0DMS8 6/20 0.45
ADORA2B P29275 3/20 0.45
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
KDM4E B2RXH2 3/20 0.45
NPC1 O15118 3/20 0.45
ALOX15 P16050 1/20 0.45
PKM P14618 1/20 0.45
HTT P42858 1/20 0.45
GSK3B P49841 2/20 0.44
HDAC2 Q92769 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
RAB9A P51151 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4145542 0.94 NAMPT (0.49) NAMPTCACNA1BAPBA1ADORA2AADORA1
SCHEMBL4150171 0.90 GSK3B (0.47) NAMPTCACNA1BAPBA1ADORA2AADORA1
SCHEMBL4164633 0.88 GSK3B (0.47) NAMPTCACNA1BAPBA1ADORA2AADORA1
SCHEMBL4161472 0.87 GSK3B (0.53) NAMPTCACNA1BAPBA1ADORA2AADORA1
SCHEMBL4157386 0.85 GSK3B (0.59) NAMPTCACNA1BAPBA1MEN1KMT2A
SCHEMBL4161610 0.85 GSK3B (0.43) NAMPTCACNA1BAPBA1ADORA2AADORA1
SCHEMBL4152170 0.85 GSK3B (0.47) NAMPTCACNA1BAPBA1ADORA2AADORA1
SCHEMBL4157340 0.84 GSK3B (0.50) NAMPTCACNA1BAPBA1ADORA2AADORA1
SCHEMBL4153463 0.84 GSK3B (0.41) NAMPTCACNA1BAPBA1ADORA2AADORA1
SCHEMBL4959799 0.84 GSK3B (0.42) NAMPTCACNA1BAPBA1ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 NAMPT 1225/4885CACNA1B 4611/4885APBA1 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.